Global
Include All CSL Behring Country Sites
About CSL
Our Businesses
Our Products
Research and Development
Recent Highlights
Investment in R&D
Core Capabilities
Centres of Excellence
Product Pipeline
Clinical Trials
Business Development
Investors
Newsroom
Careers
Contact CSL
|
CSL Websites
|
Site Map
|
Glossary
Home
> Research and Development
Research and Development
Contact
CSL R&D
Based in Melbourne, the
Biopharmaceutical Formulation Centre was constructed in 2007 to provide service to formulation and finishing of liquid pharmaceuticals.
CSL is a global specialty biopharmaceutical company that develops important, new, protein-based medicines that save lives by preventing or treating serious medical conditions. We do this by using our core capabilities in plasma therapeutics, vaccines, our ISCOMATRIX
®
adjuvant and recombinant biotechnology.
CSL includes CSL Behring, ZLB Plasma, CSL Biotherapies and CSL Bioplasma. These four businesses have a combined heritage of outstanding contributions to medicine and human health, with more than 100 years experience in the development and manufacture of vaccines and plasma protein biotherapies.
Our strong commitment to funding research and development of protein based medicines for unmet medical needs underpins our continued growth.
CSL operates as one integrated global research and development organisation. We assemble co-ordinated global project teams that leverage core capabilities at each of our sites, maximise expertise and minimise duplication.
R&D Partnerships
CSL maintains strong long-standing strategic partnerships with academic institutions and other corporations in Australia, North America and Europe. These collaborative partnerships support a range of effective research programs, including both basic and applied research in plasma therapeutics, vaccines and recombinant biotechnology.
R&D Briefing Dec 2007
R&D Briefing Dec 2006
R&D Briefing Dec 2005
R&D Briefing Dec 2004
© 2008 CSL Limited